(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.16%) $83.51
(-0.20%) $2.47
(0.15%) $2 342.40
(0.48%) $29.76
(0.43%) $993.00
(0.06%) $0.931
(0.16%) $10.66
(0.04%) $0.791
(0.00%) $86.75
Live Chart Being Loaded With Signals
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases...
Stats | |
---|---|
Today's Volume | 561 518 |
Average Volume | 793 998 |
Market Cap | 1.82B |
EPS | $-0.490 ( Q1 | 2024-05-08 ) |
Next earnings date | ( $-0.410 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-23.66 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0850 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-28 | Baker Bros. Advisors Lp | Buy | 12 925 | Non-Qualified Share Option (right to buy) |
2024-05-28 | Krishana Ranjeev | Buy | 0 | |
2024-05-28 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
2024-05-28 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
2024-05-28 | Baker Bros. Advisors Lp | Buy | 674 261 | Non-Voting Ordinary Shares |
INSIDER POWER |
---|
-72.39 |
Last 69 transactions |
Buy: 693 246 | Sell: 4 752 433 |
Volume Correlation
Immunocore Holdings plc Correlation
10 Most Positive Correlations | |
---|---|
SMSI | 0.931 |
FXNC | 0.918 |
WKME | 0.917 |
SIRI | 0.912 |
PDCO | 0.909 |
TTEC | 0.907 |
BSBK | 0.902 |
UONEK | 0.899 |
CNTG | 0.899 |
EEIQ | 0.898 |
10 Most Negative Correlations | |
---|---|
BLIN | -0.941 |
IINN | -0.938 |
CEG | -0.932 |
ROOT | -0.925 |
PPC | -0.925 |
FANG | -0.918 |
NRIX | -0.918 |
APP | -0.917 |
CRAI | -0.914 |
ENTX | -0.912 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Immunocore Holdings plc Correlation - Currency/Commodity
Immunocore Holdings plc Financials
Annual | 2023 |
Revenue: | $249.43M |
Gross Profit: | $248.39M (99.58 %) |
EPS: | $-1.130 |
FY | 2023 |
Revenue: | $249.43M |
Gross Profit: | $248.39M (99.58 %) |
EPS: | $-1.130 |
FY | 2022 |
Revenue: | $143.74M |
Gross Profit: | $143.28M (99.68 %) |
EPS: | $-0.900 |
FY | 2021 |
Revenue: | $26.52M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-3.10 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators